AAV for pain: steps towards clinical translation

Area of Science:

• Neuroscience
• Gene Therapy
• Pain Management

Background:

• Neuropathic pain presents a significant challenge in clinical practice, with limited effective long-term therapeutic options.
• Current analgesic drug development faces hurdles in clinical validation and the availability of suitable small-molecule therapeutics for novel targets.
• Recombinant adeno-associated virus (rAAV) vectors offer a potential gene therapy strategy for sustained pain relief.

Purpose of the Study:

• To review the therapeutic potential of rAAV vectors for targeting primary sensory neurons to control neuropathic pain.
• To examine the preclinical development and clinical translation of rAAV-based gene therapy for pain management.
• To discuss the role of gene therapy in addressing limitations in analgesic drug development.

Main Methods:

• Review of existing literature on rAAV vector biology, including self-complementary genomes and capsid selection.
• Analysis of safety considerations and immunological data from rAAV clinical trials in other disease areas.
• Examination of preclinical studies involving intrathecal rAAV delivery in rodent pain models.

Main Results:

• rAAV vectors can efficiently target primary sensory neurons for long-term pain control via analgesic gene expression.
• Intrathecal rAAV delivery in rodent models demonstrates potential for neuropathic pain management.
• Gene therapy using rAAV can facilitate first-into-human trials for novel pain targets.

Conclusions:

• rAAV gene therapy represents a promising avenue for developing novel, long-term treatments for neuropathic pain.
• This approach can overcome limitations in traditional analgesic drug development by enabling testing of previously inaccessible targets.
• Further preclinical development is crucial for the clinical translation of rAAV-based pain therapies.